Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen vs Thalidomide in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00041080Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2003
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thalidomide in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Feb 2003; status: completed.
02
Drugs
thalidomide
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00041080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041080.